Brief: Helix Biopharma says till date L-DOS47 continues to be well tolerated by patients
04/03/2016 24:25
March 3 (Reuters) - Helix Biopharma Corp HBP.TO : * Reports on advancement of its lung cancer drug candidate L-DOS47 * Says there have been no dose limiting toxicities reported to-date and L-DOS47 continues to be well tolerated by patients * Source text for Eikon urn:newsml:reuters.com:*:nCCN5sGSZb * Further company coverage HBP.TO ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020